Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRANSFORM: GSK3915393 in Idiopathic Pulmonary Fibrosis
2023-509371-16-00Phase 2Completed
- Sponsor
- GSK
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 2, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing GSK3915393 with Placebo (2 arms). Primary endpoint: Absolute change from baseline in FVC (mL) at Week 26. Started May 2024; status: completed.
02
Drugs
GSK3915393
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on 2023-509371-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509371-16-00.